TerminatedPhase 1

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

Stopped: reprioritization

Israel5 participantsStarted 2024-08-01

Plain-language summary

This is an open label study to evaluate the safety and initial efficacy of intra-articular administration of Allocetra in patients with Psoriatic Arthritis (PsA).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosed with PsA.
✓. Stage 1 patients:
✓. Stage 2 patients:
✓. Acceptable blood tests- Complete Blood Count (CBC), electrolytes, adequate renal function, adequate liver function.

Exclusion criteria

✕. Prior intra-articular injection to the target joint of steroids, hyaluronate or other drugs within 3 months prior to treatment.
✕. Any significant injury to the target joint within the 6 months prior to treatment, or any surgery to the target joint within the 12 months prior to treatment.
✕. Findings of acute fractures, severe loss of bone density, chondrocalcinosis and/or severe bone or joint deformity in the target joint.
✕. Evidence of active local infection in the target joint.
✕. Concomitant rheumatic, inflammatory or autoimmune disease other than PsA.
✕. Other limb pain of unknown etiology.
✕. Any evidence of clinically significant active infection.
✕. Major medical condition as detailed in the protocol.

What they're measuring

Primary outcome

Timeframe: 12 months

Trial details

NCT IDNCT06522035

SponsorEnlivex Therapeutics Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-10-20

View on ClinicalTrials.gov More Arthritis, Psoriatic trials